Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Entera Bio Ltd. Director's Dealing 2025

Jan 17, 2025

35604_dirs_2025-01-17_a4ddb7d1-bf81-42ab-95e4-ddb378d0e3fb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Entera Bio Ltd. (ENTX)
CIK: 0001638097
Period of Report: 2025-01-15

Reporting Person: Taitel Haya (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-01-15 Ordinary Shares, par value NIS 0.0000769 per share A 6922 Acquired 64650 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-01-15 Stock Option (right to buy) $2.28 A 28509 Acquired 2035-01-15 Ordinary Shares, par value NIS 0.0000769 per share (28509) Direct

Footnotes

F1: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.

F2: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.